Toho Holdings Company Limited operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Toho Holdings Company Limited with three other
drug stores in Asia:
Huadong Medicine Company Limited
sales of 25.38 billion Chinese Renmimbi [US$3.69 billion]
of which 79%
Shanghai Pharmaceutical Company Limited
(120.76 billion Chinese Renmimbi [US$17.55 billion]
Vital KSK Holdings Incorporation
(621.04 billion Japanese Yen [US$5.59 billion]
of which 95%
was Pharmaceuticals Sales).
During the year ended March of 2016, sales at
Toho Holdings Company Limited were ¥1.31 trillion (US$11.78 billion).
increase of 12.6%
versus 2015, when the company's sales were ¥1.16 trillion.
Sales of Institutional Support for Clinical Trial saw an increase
that was more than double the company's growth rate: sales were up
43.5% in 2016, from
¥370.00 million to ¥531.00 million.
Not all segments of Toho Holdings Company Limited experienced an increase in sales in 2016:
sales of Information Equipment Sales fell 13.5% to ¥1.21 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).